We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Icosavax

News List

Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 03, 2021
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Vaccine biotech Icosavax sets terms for $150 million IPO firstwordpharma
July 23, 2021
Icosavax plans to raise $150 million in its initial public offering by offering 10 million shares at a price range of $14 to $16, as reported by NASDAQ.
Icosavax raises funding to advance RSV/hMPV vaccine programme pharmaceutical-technology
April 08, 2021
Icosavax has raised $100m through a Series B financing round to support the development of its bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine programme through initial clinical studies.